Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy
{{output}}
Prostate cancer (PCa) is a leading malignancy, and progression to castration-resistant prostate cancer (CRPC) remains a central therapeutic challenge. Cuproptosis, a copper-dependent cell death mechanism first characterized in 2022, is triggered by copper bind... ...
